Pharmaceutical

Zambon gains Chinese regulatory authority approval for Fluimucil IV

Zambon Pharma has received approval from Chinese regulatory authorities and launched Fluimucil (N-acetylcysteine).

Jun 25, 2025 - 06:00
Zambon gains Chinese regulatory authority approval for Fluimucil IV
Zambon Pharma has received approval from Chinese regulatory authorities and launched Fluimucil (N-acetylcysteine).
Read the original article

Tags:

Previous Article

Overcoming technical challenges in gene therapy product fill-finish operations

Next Article

Navamedic signs agreement to acquire dne pharma

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA grants access to new class of paediatric diabetes medicine

FDA grants access to new class of paediatric diabetes m...

Jun 21, 2023

Opinion: Hospital systems have to decide: Do they want to be Apple or Android?

Opinion: Hospital systems have to decide: Do they want ...

Nov 15, 2023

Moderna concludes construction at new mRNA vaccine facility in Canada

Moderna concludes construction at new mRNA vaccine faci...

Feb 26, 2024